Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Gastrointestinal pathogenic microorganisms comprise a diverse group of bacteria, viruses, and parasites that cause enteric diseases by disrupting intestinal homeostasis. Key bacterial pathogens include Salmonella enterica, Escherichia coli, and Clostridioides difficile, while viral agents such as Norovirus and Rotavirus are leading causes of acute gastroenteritis (StatPearls, 2023). These organisms employ various virulence factors, including enterotoxins and adhesion proteins, to colonize the gut mucosa and elicit inflammatory responses (Nature Reviews Microbiology, 2013). Pharmacological intervention typically targets microbial-specific processes, such as cell wall synthesis (beta-lactams) or DNA replication (fluoroquinolones), to eliminate the infection (CDC, 2024). However, the lack of specificity in many current treatments often leads to collateral damage to the host's commensal microbiome, increasing the risk of secondary infections like C. difficile (NIH, 2022). Consequently, drug development is increasingly focused on narrow-spectrum agents and anti-virulence strategies to minimize ecological disruption within the gut (PubMed, 2021).
Antimicrobial agents targeting these microorganisms function by inhibiting essential cellular processes, including cell wall synthesis, protein translation, nucleic acid replication, and metabolic pathways specific to the pathogen.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gastrointestinal pathogenic microorganisms.